Centiva Capital’s Lexaria Bioscience LEXX Stock Holding History

Centiva Capital’s Portfolio LEXX Stock Details LEXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-804	Closed	-$32.8K	–	1821
2023 Q1	$32.8K	Sell	804 -67	-8%	-$2.86K	﹤0.01%	1402
2022 Q4	$32K	Sell	871 -13	-1%	-$467	﹤0.01%	1264
2022 Q3	$32K	Sell	884 -60	-6%	-$2.56K	﹤0.01%	1357
2022 Q2	$42K	Buy	+944	New	+$38K	﹤0.01%	1477

Other funds holding LEXX

ICM

Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

1832 Asset Management Toronto, Ontario, Canada $199B AUM 37.98% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

APC

Aspire Private Capital Cornelius, North Carolina $484M AUM 17.28% 1-Year Est. Return

Centiva Capital's LEXX Position: Q2 2023 in Review

Centiva Capital sold out of Lexaria Bioscience (LEXX) in Q2 2023, closing a stake of 804 shares — an estimated $32.8K sold.

Centiva Capital first reported a position in LEXX in Q2 2022 and held it in 4 quarters. The position peaked at $42K in Q2 2022. 14 funds tracked by Wall St. Rank hold LEXX as of Q2 2023.

Centiva Capital reported no remaining Lexaria Bioscience position as of Q2 2023 after selling out during the quarter.
Centiva Capital sold 804 Lexaria Bioscience shares in Q2 2023, an estimated $32.8K.
Centiva Capital first reported a position in Lexaria Bioscience in Q2 2022 and held it in 4 quarters.
Centiva Capital's Lexaria Bioscience position peaked at $42K in Q2 2022.
14 funds tracked by Wall St. Rank held Lexaria Bioscience as of Q2 2023.

Based on Centiva Capital's 13F filing for Q2 2023, filed 14 Aug 2023.